Medical Advocates
HIV/HBV Coinfection
 
Drugs
 
General  Reports
Adefovir 
 Atazanavir 
Darunavir
Efavirenz
 Elvitegravir/Cobicistat/ Emtricitabine/
  Tenofovir Alafenamide
Entecavir
Fosamprenavir
 Lamivudine		 Lopinavir
Maraviroc
Nelfinavir
Pegylated IFN-alpha2a
Sofosbuvir
Sorafenib
Raltegravir
Tenofovir
 Tenofovir/Emtricitabine
ARVs: General
HIV/HBV Main Page Main New/Newsworthy  Home Page
Last Update:  May 12, 2017  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
     Journal Papers, Abstracts, and Commentaries
 
 
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Archampong TN, Boyce CL, Lartey M, et al
Antivir Ther. 2016 May 11.
 Abstract

Virologic and Serologic Outcomes of Mono vs. Dual HBV Therapy and Characterization of HIV/HBV Coinfection in a US Cohort.
 Kang M, Hollabaugh K, Pham V,  et al
J Acquir Immune Defic Syndr. 2014 Apr 1.
 Abstract

Hepatotoxicity of antiretrovirals in patients with human immunodeficiency virus and viral hepatitis coinfections.
 Parenti P, Marconi L, Lupo S.
J Int AIDS Soc. 2012 Nov 11;15(6):18431
 Abstract
Atazanavir
 
     Journal Papers, Abstracts, and Commentaries
 
 
Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected,
Treatment-Experienced HIV Patients.
 Pérez-Elías MJ, Gatell JM, Flores J, et al
HIV Clin Trials. 2009 Jul-Aug;10(4):269-75|
 Abstract

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients
co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract
Darunavir
 

     Journal Papers, Abstracts, and Commentaries
 

  Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in
Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007 Jul-Aug;8(4):213-20.
Abstract
Efavirenz
 

     Journal Papers, Abstracts, and Commentaries

 
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic
hepatitis B or C.
 Meynard JL, Lacombe K, Poirier JM,  et al
 J Antimicrob Chemother. 2009 Jan 23.
 Abstract

Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM
of EFV.
 Katsounas A, Frank A, Klinker H, Langmann P. 
Eur J Med Res. 2007 Aug 16;12(8):331-6
Abstract
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
 

     Journal Papers, Abstracts, and Commentaries
 

  Efficacy and Safety of Switching to a Single-Tablet Regimen of  (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults.
 Gallant J, Brunetta J, Crofoot G, et al
J Acquir Immune Defic Syndr. 2016 May 1
Abstract
Entecavir
 
     Journal Papers, Abstracts, and Commentaries
 
 
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
 Huang H, Li X, Zhu J, Ye S, et al
JAMA. 2014 Dec 17;312(23):2521-30
 Abstract

Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir/emtricitabine)
experienced patients.
Ratcliffe L, Beadsworth MB, Pennell A,  et al
AIDS. 2011 Feb 22.
 Abstract

A case of HIV coinfected with hepatitis B virus treated by entecavir.
 Yamada A, Sako A, Nishimura S, et al  
 Nippon Shokakibyo Gakkai Zasshi. 2009 Dec;106(12):1758-63
 Abstract

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine
as part of antiretroviral therapy.
 Pessôa MG, Gazzard B, Huang AK, et al 
AIDS. 2008 Sep 12;22(14):1779-87.
 Abstract
 
A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir
 Fukushima K, Ueno Y, Inoue J, et al 
Hepatol Res. 2008 May 20
 Abstract
 
Lack of an Effect of HIV Co-Infection on the Pharmacokinetics of Entecavir in HBV
Infected Patients.
 Zhu M, Bifano M, Xu X, et al
Antimicrob Agents Chemother. 2008 Apr 7
 Abstract

The anti-HIV antiviral activity of entecavir: The loss of a trusted friend?
 Sasadeusz J. 
J Hepatol. 2007 Oct 1;
 Abstract
Fosamprenavir
 
     Journal Papers, Abstracts, and Commentaries
 
 
Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1-Infected Patients With |
or Without Hepatitis B or C Coinfection.
 Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M.
HIV Clin Trials. 2012 May-Jun;13(3):171-
 Abstract
Lopinavir
 

     Journal Papers, Abstracts, and Commentaries

  Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment.
 Khaykin P, Kotzerke P, Stephan C, et al
Ther Drug Monit. 2014 Apr;36(2):192-201
 Abstract
Maraviroc
 
     Journal Papers, Abstracts, and Commentaries
 
 
Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
Crespo M, Navarro J, Moreno S, et al
Enferm Infecc Microbiol Clin. 2016 Apr 6.
 Abstract

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
Rockstroh JK, Soriano V, Plonski F, et al
HIV Clin Trials. 2015 Apr;16(2):72-80.
 Abstract

Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the
Maraviroc Expanded Access Program.
Lazzarin A, Than S, Valluri SR, et al
HIV Clin Trials. 2012 Mar-Apr;13(2):83-9
 Abstract
Nelfinavir
 

     Journal Papers, Abstracts, and Commentaries

  Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and
human immunodeficiency virus infection.
 Benator DA, Weiner MH, Burman WJ, et al
Pharmacotherapy. 2007 Jun;27(6):793-800.
Abstract
Pegylated IFN-alpha2a
 

     Journal Papers, Abstracts, and Commentaries

  FULL-TEXT ARTICLE
 Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report.
 Delicio AM, Abati PA, Vigani AG.
J Venom Anim Toxins Incl Trop Dis. 2013 Dec 10;19(1):31.
Paper

Safety and Tolerability of Sequential Pegylated IFN-alpha2a and Tenofovir for Hepatitis B
Infection in HIV+ Individuals.
Johnson; Ristig; Overton; et al
HIV Clin Trials. 2007 May-Jun;8(3):173-81.
Abstract
Raltegravir
 
   Journal Papers, Abstracts, and Commentaries
 
  Safety and efficacy of raltegravir in patients co-infected with HIV and hepatitis B and/or C virus: complete data from Phase III double-blind studies.
Rockstroh J, Sklar P, Wan H,  
J Int AIDS Soc. 2012 Nov 11;15(6):18415.
Abstract

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals.
Cevik M, Jagjit Singh G, Dickinson L, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):18419
 Abstract

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M,  et al
J Antimicrob Chemother. 2012 Sep 14.
Abstract
Rilpivirine
 
     Journal Papers, Abstracts, and Commentaries
 
  Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/
hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M, Amaya G, Clumeck N, et al
 J Antimicrob Chemother. 2012 Apr 23
 Abstract
Sofosbuvir
 

     Journal Papers, Abstracts, and Commentaries

  Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
 Todesco E, Demeret S, Calin R, Roque-Afonso AM,  
AIDS. 2017 Jun 1;31(9):1346-1348.
Abstract
Sorafenib
 

     Journal Papers, Abstracts, and Commentaries

  Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient:
Possible synergy with HAART ? A case report.
Chelis L, Ntinos N, Souftas V,  et al
Med Oncol. 2011 Dec;28 Suppl 1:165-8.
Abstract

Complete response after sorafenib therapy for hepatocellular carcinoma in an
HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
 Chelis L, Ntinos N, Souftas V,  et al
Med Oncol. 2010 Aug 31.
Abstract
Antiretrovirals: General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
HIV outcomes in Hepatitis B virus coinfected individuals on HAART.
 Chun HM, Mesner O, Thio CL,  et al
J Acquir Immune Defic Syndr. 2014 Apr 1.
 Abstract

Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.
 Hoffmann CJ, Seaberg EC, Young S, et ala
AIDS. 2009 Jun 22
 Abstract

Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C,
and Human Immunodeficiency Virus Infection.
 Hofmann WP, Soriano V, Zeuzem S.
Handb Exp Pharmacol. 2009;189:321-346.
 Abstract
 
Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment
and outcome in HIV-infected individuals: a nationwide cohort study.
 Omland LH, Weis N, Skinhøj P, et al 1:
HIV Med. 2008 May;9(5):300-6.
 Abstract
 
Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus
monoinfection and coinfection with HIV.
Locarnini S, Warner N. 
Antivir Ther. 2007;12 Suppl 3:H15-23.
 Abstract
 
Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and
HIV-HCV infection.
 Cooper CL, Mills E.
Int J STD AIDS. 2007 Aug;18(8):546-50.
 Abstract
 
Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis
B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART
and HBV Surface and Early Antigen Seroconversion.
Miailhes P, Trabaud MA, Pradat P, et al
Clin Infect Dis. 2007 Sep 1;45(5):624-32.
 Abstract
 
Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients
Receiving Anti-HBV Active Antiretroviral Therapy.
Nunez M, Ramos B, Diaz-Pollan B, et al
AIDS Res Hum Retroviruses. 2006 Sep;22(9):842-8.
 Abstract

Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls.
Levy V, Grant RM.
Clin Infect Dis. 2006 Oct 1;43(7):904-10.
Abstract
 

HIV/HBV Main Page Main New/Newsworthy  Home Page

HIV/HBV Drugs